FDA-approved
Sexual & reproductive
Nafarelin
Evidence
FDA approved
Class
GnRH agonist
KEY TAKEAWAY
Nafarelin is a synthetic GnRH agonist that is sprayed into the nose. It is sold as Synarel. The FDA approved nafarelin (Synarel) in 1990 for endometriosis and for central precocious puberty.
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH agonist
Approved for
Endometriosis and central precocious puberty
Key fact
The FDA approved nafarelin (Synarel) in 1990 for endometriosis and for central precocious puberty.
Route
Nasal spray, usually twice a day
Evidence strength
FDA approved
Nafarelin is a synthetic GnRH agonist that is sprayed into the nose. It is sold as Synarel.
It first stimulates and then desensitizes GnRH receptors, which lowers estrogen production.
The FDA approved nafarelin (Synarel) in 1990 for endometriosis and for central precocious puberty.
Endometriosis and central precocious puberty.
Hot flashes, reduced libido, bone density loss and nasal irritation are common.
U.S. FDA prescribing information for Nafarelin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.